期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 6, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s40425-018-0391-1
关键词
Melanoma; Adoptive cell therapy; Tumor-infiltrating lymphocytes; Immunotherapy; Lymphodepletion; Interleukin-2; Antigen recognition; Combination therapy
资金
- NEON therapeutics
- BMS
- Merck
- Novartis
- Medimmune
The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical trials executed in several specialized centers over the world. Even in the era of targeted therapy and immune checkpoint inhibition, TIL therapy can be an additional and clinically relevant treatment line. This review provides an overview of the clinical experiences with TIL therapy thus far, including lymphodepleting regimens, the use of interleukin-2 (IL-2) and the associated toxicity. Characteristics of the TIL products and the antigen recognition pattern will be discussed, as well as the current and upcoming production strategies, including the selective expansion of specific fractions from the cell product. In addition, the future potential of TIL therapy in melanoma and other tumor types will be covered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据